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Prior failed ipsilateral percutaneous endovascular
intervention in patients with critical limb ischemia
predicts poor outcome after lower extremity
bypass
Brian W. Nolan, MD, MS,a Randall R. De Martino, MD,a David H. Stone, MD,a Andres Schanzer, MD,b
Philip P. Goodney, MD, MS,a Daniel W. Walsh, MD,a and Jack L. Cronenwett, MD,a for the Vascular Study
Group of New England, Lebanon, NH; and Worcester, Mass
Background: Although open surgical bypass remains the standard revascularization strategy for patients with critical limb
ischemia (CLI), many centers now perform peripheral endovascular intervention (PVI) as the first-line treatment for
these patients. We sought to determine the effect of a prior ipsilateral PVI (iPVI) on the outcome of subsequent lower
extremity bypass (LEB) in patients with CLI.
Methods: A retrospective cohort analysis of all patients undergoing infrainguinal LEB between 2003 and 2009 within
hospitals comprising the Vascular StudyGroup of NewEngland (VSGNE)was performed. Primary study endpoints were
major amputation and graft occlusion at 1 year postoperatively. Secondary outcomes included in-hospital major adverse
events (MAE), 1-year mortality, and composite 1-year major adverse limb events (MALE). Event rates were determined
using life table analyses and comparisons were performed using the log-rank test. Multivariate predictors were
determined using a Cox proportional hazards model with multilevel hierarchical adjustment.
Results: Of 1880 LEBs performed, 32% (n  603) had a prior infrainguinal revascularization procedure (iPVI, 7%;
ipsilateral bypass, 15%; contralateral PVI, 3%; contralateral bypass, 17%). Patients with prior iPVI, compared with those
without a prior iPVI, were more likely to be women (32 vs 41%; P  .04), less likely to have tissue loss (52% vs 63%;
P  .02), more likely to require arm vein conduit (16% vs 5%; P  .001), and more likely to be on statin (71% vs 54%;
P .01) and beta blocker therapy (92% vs 81%; P .01) at the time of their bypass procedure. Other demographic factors
were similar between these groups. Prior PVI or bypass did not alter 30-day MAE and 1-year mortality after the index
bypass. In contrast, 1-year major amputation and 1-year graft occlusion rates were significantly higher in patients who
had prior iPVI than those without (31% vs 20%; P .046 and 28% vs 18%; P .009), similar to patients who had a prior
ipsilateral bypass (1 year major amputation, 29% vs 20%; P  .022; 1 year graft occlusion, 33% vs 18%; P  .001).
Independent multivariate predictors of higher 1-year amputation and graft occlusion rates were prior iPVI, prior
ipsilateral bypass, dialysis dependence, prosthetic conduit and distal (tibial and pedal) bypass target.
Conclusions: Prior iPVI is highly predictive for poor outcome in patients undergoing LEB for CLI with higher 1-year
amputation and graft occlusion rates than those without prior revascularization, similar to prior ipsilateral bypass These
findings provide information, which may help with the complex decisions surrounding revascularization options in
patients with CLI. (J Vasc Surg 2011;54:730-6.)
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hAlthough open surgical bypass provides the most
durable option for limb salvage in patients with critical
limb ischemia (CLI),1 it has substantial morbidity and
mortality. Thus, many centers prefer to initially treat CLI
patients with a less-invasive endovascular peripheral en-
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730ovascular intervention (PVI) instead of open bypass.
esults of the Bypass versus Angioplasty in Severe Isch-
emia of the Leg (BASIL) trial suggest that overall
ifferences in amputation-free survival (AFS) after PVI vs
ypass are insignificant.2,3
Although the potential benefit of less-invasive PVI is
lear, the potential negative impact of PVI on ultimate limb
alvage in CLI patients is unclear. In the BASIL Trial,
atients undergoing bypass after a failed PVI had worse
FS than those undergoing primary bypass.3,4 Addition-
lly, previous studies have suggested that patients who
ailed PVI and went on to require bypass needed longer
ypasses to more distal targets.5,6 These findings have
timulated debate over PVI vs bypass as the optimal first-
ine strategy for the treatment of CLI.
The outcome of secondary lower extremity bypass after
ailed primary bypass is known to be poor, with significantly
igher graft occlusion and amputation rates.7,8 However,
he outcome of lower extremity bypass after failed ipsilat-
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Volume 54, Number 3 Nolan et al 731eral PVI (iPVI) is not established. The purpose of this study
is to assess the effect of a failed prior PVI on the outcome of
infrainguinal bypass performed for CLI and to compare the
magnitude of this effect with the impact of a failed previous
bypass graft.
METHODS
Study design, sample, and database. This is a retro-
spective cohort analysis of 1880 infrainguinal bypass grafts
performed between January 2003 and December 2009 for
CLI (rest pain or tissue loss) in 10 centers participating in
the Vascular Study Group of New England (VSGNE). The
VSGNE is a regional cooperative quality improvement
initiative developed by community and academic centers in
2002 to study regional outcomes in vascular surgery. Fur-
ther details on this registry have been published previously9
and are available at http://www.vsgne.org. In the VSGNE
registry, we collect over 70 preoperative, intraoperative,
and postoperative variables, as well as key outcomes at
1-year follow-up, as described in previous publications.9,10
Historical information collected at the time of surgery
indicated that 32% (n 603) of patients had undergone an
infrainguinal revascularization procedure at some time
prior to the index bypass procedure being entered into the
VSGNE registry. These consisted of 7% (n  132) iPVI,
15% (n 275) ipsilateral bypass, 3% (n 62) contralateral
PVI, and 17% (n 326) contralateral bypass. One hundred
ninety-four patients (10%) underwent multiple revascular-
ization procedures. These are shown in the Appendix (on-
line only). The number of patients undergoing bypass with
a history of a prior ipsilateral PVI varied substantially
among centers, ranging from 2% to 13% (data not shown)
and the observed variation was used to adjust for outcomes
in our statistical modeling. Details of these previous proce-
dures were not further recorded, so timing and precise type
of previous bypass or PVI is not known.
Study endpoints. To evaluate the outcomes of lower
extremity bypass (LEB) following a failed PVI, we chose
our study endpoints to target safety and efficacy of the
procedure as previously described.11 The principal efficacy
outcomes of this study were major amputation (above or
below knee) and graft occlusion within the first year post-
operatively to evaluate efficacy of LEB. The safety out-
comes included in-hospital major adverse events (myocar-
dial infarction, congestive heart failure, dysrhythmia
requiring treatment, wound infection, renal insufficiency,
respiratory failure, pneumonia, graft infection, return to the
operating room, death, graft occlusion, or major amputa-
tion). Additional efficacy outcomes included 1-year mor-
tality and 1-year major adverse limb events (major adverse
limb events [MALE]major above-knee amputation, new
bypass, jump graft/interposition graft, graft occlusion or
major reintervention requiring thrombectomy or throm-
bolysis).11
Definitions of patient medical comorbidities in the
VSGNE have been defined elsewhere.12 These include
chronic obstructive pulmonary disease (COPD; chart his-
tory), congestive heart failure (CHF; chart history or doc- pmented ejection fraction 50% on preoperative testing),
oronary artery disease (CAD; any history of angina, myo-
ardial infarction [MI], prior coronary intervention, or
lectrocardiogram [EKG] changes consistent with previous
I), chronic renal insufficiency (CRI; Cr 1.8 mg/dL),
nd-stage renal disease (ESRD; on dialysis), diabetes mel-
itus (DM; chart history, designated as diet-controlled, on
ral hypoglycemic agents, or on insulin), and hypertension
HTN; chart history or blood pressure 140/90), hyper-
ipidemia (HLIP; chart history). For our analysis, distal
ypass included tibial and pedal targets.
Analysis. Demographic data were compared using a t
est for continuous variables and 2 with Fischer exact
orrection for categorical or dichotomous variables. Rates
ere determined using Kaplan–Meier life table analyses.
omparisons of rates were made using the log-rank test.
ultivariate predictors of major amputation and graft oc-
lusion were determined using Cox proportional hazards
odels. Univariate predictors for outcomes identified in
able I were tested in our multivariate model and those
hat were significant were included in the multivariate
odel, including graft type and target vessel. Multilevel
hierarchical) modeling was performed to account for dif-
erences in outcomes across centers. All analyses were per-
ormed using Microsoft Excel (Redmond, Wash) and Stata
College Station, Tex). The Institutional Review Board at
artmouth Medical School approved the analysis of de-
dentified data from our registry for this study.
ESULTS
Most demographic factors were similar when compared
etween those who underwent prior iPVI and those who
id not (Table I). However, patients who had been treated
ith prior iPVI were less likely to have tissue loss, were
ore likely to be women, were more likely to be on statin
herapy and beta blocker therapy at the time of their index
ypass, and weremore likely to require arm vein for conduit
P .05). Although there was a tendency for these patients
o require more distal, tibial bypass targets, this finding was
ot statistically significant and their subsequent outcome
as not changes.
Overall, in-hospital major adverse events occurred in
7% of patients after bypass for CLI in VSGNE with no
rior revascularization procedures. This event rate was not
ffected by whether or not a patient had undergone previ-
us iPVI or bypass (Table II). Similarly, 1-year mortality
12%) was not different among these groups (Table II).
Major amputation by 1 year postoperatively, however,
as significantly more likely after infrainguinal bypass if
atients had a prior iPVI, at 31% (P  .046), or prior
ypass, at 29% (P  .022), compared with 20% in patients
ithout prior revascularization procedures (Fig 1). Prior
ontralateral procedures (PVI or bypass) were not associ-
ted with a higher rate of amputation (Fig 1). Similarly, the
-year graft occlusion rate was significantly higher in pa-
ients who had prior iPVI, at 28% (P  .009), or prior
ypass at 33% (P  .001), compared with only 18% in
atients without prior ipsilateral revascularization (Fig 2).
l
o
D
P
l
i
l
n
t
e
p
8
p
F
l
t
r
JOURNAL OF VASCULAR SURGERY
September 2011732 Nolan et alAs a combined endpoint, MALE were significantly more
likely in patients with prior iPVI, or bypass (Fig 3).
By multivariate analysis, predictors of 1-year major
amputation rate were prior ipsilateral PVI or bypass, dialysis
dependence, prosthetic conduit, and tibial level bypass
target. Aspirin was found to be protective. Prior ipsilateral
PVI or bypass similarly increased the risk of major amputa-
tion by approximately 50% in addition to dialysis depen-
dence, prosthetic conduit, and tibial level target. Aspirin
use was protective of amputation at 1 year (Table III).
Finally, prior ipsilateral PVI and bypass also increased the
risk of 1-year graft occlusion by 50% (Table IV). Dialysis
Table I. Patient characteristics
Ipsila
No prior revasca (n1277) PVI (n
Age 70 68
Male 68% 59%
Tobacco use 80% 82%
Hypertension 86% 90%
Diabetes 56% 58%
CAD 40% 42%
CHF 23% 24%
COPD 31% 34%
Dialysis 10% 5%
Renal insufficiency 20% 13%
Tissue loss 63% 52%
Pre-op beta blocker 81% 92%
ASA 68% 73%
Statin 54% 71%
Prosthetic conduit 24% 29%
Arm vein conduit 5% 16%
Crural distal target 47% 53%
ASA, Aspirin; CAD, coronary artery disease; COPD, chronic obstructive pu
Renal insufficiency defines as creatinine 1.8. Coronary artery disease (CA
(COPD) defined by chart history.
aRevasc, revascularization procedure (PVI or bypass).
bP .05 (compared with no prior revascularization group).
Table II. Major adverse events (MAE) and 1-year
mortality based on prior revascularization
Type of prior
revascularization
In hospital
MAE Pa
One-year
mortality
(P valueb) Pb
No prior revascularizationa 27% 12%
Ipsilateral
Prior PVI 30% .54 13% .95
Prior bypass 28% .83 13% .51
Contralateral
Prior PVI 34% .22 13% .85
Prior bypass 35% .54 12% .36
PVI, Peripheral vascular intervention.
Major adverse events include myocardial infection, congestive heart failure,
dysrhythmia requiring treatment, wound infection, renal insufficiency, re-
spiratory failure, pneumonia, graft infection, return to the operating room,
death, graft occlusion, or major amputation.
aComparison by 2 statistic.
bComparison by log-rank statistic.dependence, prosthetic conduit, arm vein conduit, a tibial fevel bypass target, and female gender also increased the risk
f graft occlusion by multivariate analysis (Table IV).
ISCUSSION
Our study shows that a prior ipsilateral infrainguinal
VI is an important predictor of poor outcomes after
ower extremity bypass for CLI. According to multivar-
ate analysis, a prior iPVI increased both the risk of limb
oss and the risk of occlusion of a subsequent infraingui-
al bypass by approximately 50% at 1 year. This magni-
ude of effect was very similar to the negative predictive
ffect of a prior ipsilateral bypass that has reported
atency rates of only 50% to 60% and limb salvage rates of
0% at 1 year.13 Other factors identified in our risk-
rediction model have been previously reported to con-
Contralateral
) Bypass (n275) PVI (n62) Bypass (n326)
68 67 70
64% 65% 70%
88%b 84% 82%
89% 95% 94%b
57% 66%b 68%b
47%b 47% 44%
16%b 19% 21%
34% 39% 29%
5%b 15% 9%
12%b 17% 19%
49%b 53% 63%
84% 94%b 88%
66% 76% 69%
59% 69%b 61%b
46%b 39%b 32%b
17%b 11%b 15%b
54% 29%b 49%
ary disease; PVI, peripheral vascular intervention.
ongestive heart failure (CHF), and chronic obstructive pulmonary disease
ig 1. One-year major amputation rates in patients undergoing
ower extremity bypass who have undergone prior revasculariza-
ion procedure. P values compared with patients with no prior
evascularization procedure. PVI, Peripheral vascular intervention.teral
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Volume 54, Number 3 Nolan et al 733These factors include dialysis dependence, prosthetic
conduit, tibial (as opposed to popliteal) target and fe-
male gender,14-16 lending face validity to the risk predic-
tion model. Aspirin was found to be protective as previ-
ously noted by others.17 These findings lend support to
the general applicability of the VSGNE findings. In
contrast to the impact of prior ipsilateral PVI or bypass,
contralateral PVI or bypass did not affect the risk of
either amputation or graft occlusion. Thus, systemic
factors such as a hypercoagulable state are less likely to
have been responsible for the negative impact of a prior
ipsilateral procedure. Further, there were no differences
in postoperative major adverse events or 1-year mortality
between patients having primary bypass vs those who had
prior ipsilateral revascularization, suggesting that prior
ipsilateral revascularization primarily impacts graft-
related events, rather than global patient-related outcomes
such as medical, graft, or wound complications.
The BASIL trial is the only large-scale randomized
control trial to evaluate the outcomes of PVI vs bypass in
patients eligible for both. The results of our study regarding
the impact of prior PVI on AFS are similar to those pub-
lished in the BASIL Trial,3 which reported AFS at 1 year of
only 40% for bypass after failed angioplasty vs 70% after
initial bypass. Though not an endpoint of our study, cor-
responding 1-year results for AFS in VSGNE were 53% for
bypass after failed angioplasty vs 76% after initial bypass
(P  .03), very similar to the BASIL results.
The outcomes of prior failed PVI have been described
in other studies,4-6,18 but few evaluate the impact of the
PVI on subsequent bypass, as most are treated with a repeat
PVI.6,18 In a review of failed PVI, five of 46 patients with
failed PVI required subsequent bypass with a 20% amputa-
tion rate. Similarly, of 39 early (30 day) PVI failures,
Galaria et al reported that 19 required subsequent bypass
with a similar 17% rate of amputation.18 In a study of 25
bypasses after failed PVI, Böckler et al demonstrated similar
outcomes to the present study with a bypass failure rate of
50% and an amputation rate of 44% over a median of 6
Fig 2. One-year graft occlusion rates in patients undergoing
lower extremity bypass who have undergone prior revasculariza-
tion procedure. P values compared with patients with no prior
revascularization procedure. PVI, Peripheral vascular intervention.months.4 1The effect of a failed PVI on a distal anastomotic site is
ess well understood. Joels et al reported that a failed PVI
esulted in a more distal target for bypass in 28% of cases
nd half of these patients had compromised runoff as a
esult of PVI failure.5 Conversely, others have reported the
pposite. One study of 46 failed PVIs reported no change
n distal anastomosis site over a mean follow-up of 8.7
onths.6 Another reported that of 39 PVI failures, there
as no change in distal anastomotic site. This discrepancy
n the literature may be due to the small number of cases in
ach study where a failed PVI required a subsequent bypass.
hile the present study is the largest to date to report on
ypass outcome after a prior PVI, we are unable to deter-
ine if the PVI failure affected the distal target since
nformation of the index procedure is not tracked in our
atabase.
Why is prior ipsilateral PVI or bypass associated with
orse results for infrainguinal bypass? Several possible ex-
lanations exist. First, failure of prior PVI or bypass could
e a surrogate for patient-specific risk factors such as hyper-
oagulability15 that are not measured in our registry. How-
ver, this seems unlikely given that a previous failed con-
ralateral revascularization procedure was not associated
ith any negative effects. Second, a prior failed PVI or
ypass could compromise runoff for a future bypass by
mbolization or thrombosis. While this has been demon-
trated in previous reports,5 we were only able to identify a
rend (P  .15) in this cohort for secondary bypasses to
equire a more distal target artery than primary bypasses.
inally, marginal vein quality may have dictated the initial
hoice of PVI or the type of previous bypass (for example,
nitial use of prosthetic graft if vein quality was marginal). If
arginal vein was then resorted to for the subsequent
ypass, this could negatively influence graft outcome.19
ein quality used for bypass is not recorded in our registry
eyond the use of arm vein or spliced veins, which were
ncluded in our analyses. In our multivariate models, arm
ein was significantly associated with graft occlusion at 1
ear but not with major amputation.
Our study has several limitations. Most notably, we
now only that patients in our registry had undergone a
rior bypass or PVI, but we do not have data on the type of
rocedure or when it occurred. Others reporting on similar
omplications after PVI note that patients with failure
resent within 4 to 6 months after their procedure.4,5
dditionally, we do not have data on the total number of
VI procedures previously performed, which might pro-
ide a better understanding of the association between a
ailed PVI and later bypass. The VSGNE is now tracking all
VIs prospectively to assist in answering these questions.
inally, without a randomized trial, the effect of unknown
onfounders exists. Yet, we have attempted tominimize the
ffect of this with sound statistical methods in our multi-
ariate model and adjust for potential confounders such as
ifferences across centers or distal target vessels. When
ontrolling for all of these known factors, a prior PVI still
ppears to be associated with a risk of major graft events at
year.
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September 2011734 Nolan et alIn conclusion, while it is well known that a prior
failed ipsilateral infrainguinal bypass is a negative predic-
tor for future LEB success, this study demonstrates that
a prior failed infrainguinal ipsilateral PVI has a similar
negative prognostic effect on subsequent LEB. While we
are unable to definitively prove causation, prior failed
ipsilateral PVI is associated with 1-year major amputa-
tion or graft occlusion in the same manner that other
established factors such as dialysis dependence, synthetic
conduit and distal target arteries are. While some pa-
tients may benefit from an initial PVI, those who are
eligible for either procedure may benefit from bypass
given our findings and those of the BASIL trial. Further
Fig 3. Freedom from major adverse limb events after
amputation, graft occlusion, or reintervention. PVI, Peri
Table III. Independent predictors of major amputation
at 1 year
HR 95% CI
Dialysis 2.7 2.2 3.3
Prosthetic conduit 2.1 1.3 3.4
Prior ipsilateral PVI 1.5 1.1 2
Prior ipsilateral bypass 1.4 1.1 1.7
Tibial target 1.4 1.2 1.7
Aspirin 0.8 0.7 0.9
CI, Confidence interval; HR, hazard ratio; PVI, peripheral vascular inter-
vention.
Table IV. Independent predictors of graft occlusion at 1
year
HR 95% CI
Tibial target 1.9 1.6 2.4
Dialysis 1.8 1.3 2.5
Arm vein conduit 1.7 1.3 2.1
Prosthetic conduit 1.6 1.3 1.8
Prior ipsilateral PVI 1.5 1.1 2.1
Prior ipsilateral bypass 1.4 1.2 1.6
Female gender 1.3 1.1 1.5
CI, Confidence interval; HR, hazard ratio; PVI, peripheral vascular inter-
vention.work is necessary to clarify the durability, utility, and
1ost-effectiveness of a PVI-first approach for patients
resenting with CLI.
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Dr Hasan Dosluoglu (Buffalo, NY). Two quick questions.
Did you have the data that differentiated between artherectomies
as prior endovascular interventions versus others as contributing
factors? And the second one, were prior endovascular interventions
performed by vascular surgeons or other specialties and did it have
an impact?
Dr Brian W. Nolan. Unfortunately, we do not have any
information about the prior interventions. We simply know
whether they had a prior intervention or a prior bypass. We do not
know what type of intervention, be it atherectomy, angioplasty,
stent, or anything else. And, we do not know who did those
procedures or when. So unfortunately, while that would be very
interesting and potentially useful, I do not have the answer to your
question.
Dr John Jeb Hallett (Charleston, SC). Based upon the expe-
rience you have had in New England, we are forming a vascular
study group in the Carolinas now. And the question comes up:
Once you have this information, how are you using it in the study
group to try to tighten up the variability that you demonstrated in
peripheral interventions?
Dr Nolan. One of the focuses of our study group is to
examine variability and the sources of variability. We are also, of
course, interested in developing quality improvement measures we
can employ to better the care of our patients. As far as what we do
with the results of this study, first, it is probably most important for
counseling our patients: Is PVI a free shot? Well, maybe not.
Because whether or not a patient has a PVI first or a bypass, it looks
like the outcome with the subsequent procedure is the same.
Second, we have recently started a PVI database, so we will now
collect the types of information that may help us answer some of
themore complex questions about which types of interventions are
more or less successful.
Dr Paul Bloch (Portland, Me). One thing that you showed is
very interesting: Namely that bypass following endovascular inter-
vention is at higher risk for failure. You showed something that we
already knew, which is that a second bypass after a previous bypass
is at a higher risk for failure than the first one. Interestingly, it
appears that in this study, a second bypass after a prior failed bypass
had a higher failure rate than a bypass after a prior failed endovas-
cular intervention. Were those numbers significant?
Dr Nolan. No. In fact, there was no significant difference
between. Actually, they are very similar. They both seem, in our
analysis, to increase the risk of amputation, occlusion, or major
adverse limb events by about 50%. And amputation was a little bitDrMichael Silane (NewYork, NY). Youmust have hadmany
ther patients who had previous PVIs or bypasses that did very
ell. So aren’t you selecting your worst patients and therefore they
re going to have worse results than the patients who have not had
previous PVI or procedure?
Dr Nolan. That is a very good point. We do not know the
enominator, so to speak. Certainly, in the study group, we do not,
t this point, record all of our PVIs. As I mentioned, it is part of a
ew initiative. There has been plenty of successes with PVIs, and
e are really just looking at bypass after a failed PVI and how a
ailed PVI predicts the outcome of a future bypass. So in a sense,
ou are right, we do not know all the people who were treated
uccessfully with PVI. But for this study, we really were just
oncerned with the impact of a failed PVI on bypass.
Dr Christos Liapis (Athens, Greece). Do you have any infor-
ation regarding the timing of the two operations? Imean, if it was
mmediately after a failed endovascular procedure or if it was a late
vent, like a couple of years later?
Dr Nolan. Unfortunately, we do not. I did not show the data
orm, maybe that would have been helpful, but essentially, it is simple
heckbox data entry. We know the patient had a prior ipsilateral PVI,
nfrainguinal ipsilateral PVI, contralateral infrainguinal PVI, ipsilateral
uprainguinal, contralateral suprainguinal. We do not know the type
f intervention, timing of intervention, who did it, where, or anything
lse, we just know that they had an intervention.
DrMaciej Dryjski (Buffalo, NY). I would like to congratulate
ou. This is a very important message you delivered. It is the first
ime it has been so clearly presented that when we perform endo-
ascular intervention, we burn bridges for successful future by-
asses. We still do not understand the reason for that, however, it
s most likely a result of embolization. We have recently found that
istal TcpO2 decreases during, and immediately after, endovascu-
ar intervention on SFA and popliteal arteries. We do not see any
ignificant clinical markers for embolization because it probably
ffects medium-size arteries in the pedal arch.
Dr Nolan. Thank you for your comments.
DrGeorge Andros (VanNuys, Calif). For years, it seems that
he venous papers attracted the greatest number of discussants, so
am pleased to see so many speakers for an arterial paper. Your
anuscript raises questions about outcomes that need to be asked
nd answered. I would just limit my question to the simple
uestion of patency: We know when, as Chris Liapis suggested, an
rterial bypass occludes. You palpate it and it does not pulsate. All
oo often, we do not know when a peripheral intervention oc-
ludes, sometimes the patient do not get a foot pulse and we lack a
linical indicator for what is patency. Other than restoration of a
t
h
t
d
JOURNAL OF VASCULAR SURGERY
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was successful and then how did you decide it was failed?
Dr Nolan. That is a good point. And it could be that maybe I
misspoke in saying “failed.” All we know is that they had a prior
procedure. And I guess, by definition, if they needed a bypass after
having an intervention, then we would assume that the interven-
m
oion did not do what it was intended to do. But we do not actually
ave any hemodynamic information. It is possible that some pa-
ients, for example, had an SFA stent, but they still had tibial
isease. The SFA stent was doing just fine, but they required a
ore distal bypass. And we do not know specifically that it failed,
nly that they had a prior procedure.
